[1] Guttmann OP, Rahman MS, O Mahony C, et al.Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review[J]. Heart 2014, 100:465-472.
[2] Nasser MF,Gandhi S,Siegel RJ, et al. Anticoagulation for stroke prevention in patients with hypertrophic cardiomyopathy and atrial fi brillation: A review[J]. Heart Rhythm, 2021, 18(2): 297-302.
[3] Jung H, Sung JH, Yang PS, et al. Stroke risk stratification for atrial fibrillation patients with hypertrophic cardiomyopathy[J]. Am Coll Cardiol, 2018, 72(19): 2409-2411.
[4] Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. Circulation, 2011, 124(24):2761-2796.
[5] Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyo et al. pathy of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2014, 35(39):2733-2779.
[6] Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol, 2020, 76(25): 30223055.
[7] 中华医学会心血管病学分会, 中国生物医学工程学会心律分会. 心房颤动诊断和治疗中国指南[J]. 中华心血管病杂志, 2023, 51(6):572-618.
[8] Noseworthy PA, Yao X, Shah ND, et al. Stroke and Bleeding Risks in NOAC- and Warfarin-Treated Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation[J]. J Am Coll Cardiol, 2016, 67(25):3020-3021.
[9] Maron BJ. Clinical Course and Management of Hypertrophic Cardiomyopathy [J]. N Engl J Med, 2018, 379(7):655-668.?
[10] Lee SE, Park JK, Uhm JS, et al. Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy[J]. Heart. 2017, 103(19):1496-1501.
[11] January CT, Wann LS, Alpert JS, et al.ACC/AHA Task Force Members. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation[J]. J Am Coll Cardiol, 2014, 130(23):2071-2104.
[12] Kirchhof P, Benussi S, Kotecha D, et al.2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Europace, 2016, 18(11): 1609-1678.
[13] Lozier MR, Sanchez AM, Lee JJ, et al. Thromboembolic Outcomes of Different Anticoagulation Strategies for Patients with Atrial Fibrillation in the Setting of Hypertrophic Cardiomyopathy: A Systematic Review[J]. Journal of Atrial Fibrillation, 2019, 12(4): 2207.
[14] Rujirachun P, Charoenngam N, Wattanachayakul P, et al. Efficacy and safety of direct oral anticoagulants (DOACs) versus vitamin K antagonist (VKA) among patients with atrial fibrillation and hypertrophic cardiomyopathy: a systematic review and meta-analysis[J]. Acta Cardiol, 2020, 75(8): 724-732. |
